On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

被引:55
作者
Haddish-Berhane, Nahor [1 ]
Shah, Dhaval K. [1 ]
Ma, Dangshe [2 ]
Leal, Mauricio [3 ]
Gerber, Hans-Peter [2 ]
Sapra, Puja [2 ]
Barton, Hugh A. [1 ]
Betts, Alison M. [1 ]
机构
[1] Pfizer Global Res & Dev, Dept Pharmacokinet Dynam & Metab, Translat Res Grp, Groton, CT 06340 USA
[2] Pfizer Global Res & Dev, Oncol Res Unit, Pearl River, NY 10965 USA
[3] Pfizer Global Res & Dev, Dept Pharmacokinet Dynam & Metab, Pearl River, NY 10965 USA
关键词
Antibody drug conjugates; Pharmacokinetics; Pharmacodynamics; Translation; Prediction; Tumor regression; Xenograft; BRENTUXIMAB-VEDOTIN; MONOCLONAL-ANTIBODY; XENOGRAFT MODELS; CANCER MODELS; IN-VITRO; MICE; HUMANS; GROWTH; AGENTS;
D O I
10.1007/s10928-013-9329-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives of the present investigation were: (1) to compare three literature reported tumor growth inhibition (TGI) pharmacodynamic (PD) models and propose an optimal new model that best describes the xenograft TGI data for antibody drug conjugates (ADC), (2) to translate efficacy of the ADC Trastuzumab-emtansine (T-DM1) from mice to patients using the optimized PD model, and (3) to apply the translational strategy to predict clinically efficacious concentrations of a novel in-house anti-5T4 ADC, A1mcMMAF. First, the performance of all four of the PD models (i.e. 3 literature reported + 1 proposed) was evaluated using TGI data of T-DM1 obtained from four different xenografts. Based on the estimates of the pharmacodynamic/pharmacokinetic (PK/PD) modeling, a secondary parameter representing the efficacy index of the drug was calculated, which is termed as the tumor static concentration (TSC). TSC values derived from all four of the models were compared with each other, and with literature reported values, to assess the performance of these models. Subsequently, using the optimized PK/PD model, PD parameters obtained from different cell lines, human PK, and the proposed translational strategy, clinically efficacious doses of T-DM1 were projected. The accuracy of projected efficacious dose range for T-DM1 was verified by comparison with the clinical doses. Aforementioned strategy was then applied to A1mcMMAF for projecting its efficacious concentrations in clinic. TSC values for A1mcMMAF, obtained by fitting TGI data from 4 different xenografts with the proposed PK/PD model, were estimated to range from 0.6 to 11.5 mu g mL(-1). Accordingly, the clinically efficacious doses for A1mcMMAF were projected retrospectively. All in all, the improved PD model and proposed translational strategy presented here suggest that appropriate correction for the clinical exposure and employing the TSC criterion can help translate mouse TGI data to predict first in human doses of ADCs.
引用
收藏
页码:557 / 571
页数:15
相关论文
共 36 条
[1]   The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics [J].
Agoram, Balaji M. ;
Martin, Steven W. ;
van der Graaf, Piet H. .
DRUG DISCOVERY TODAY, 2007, 12 (23-24) :1018-1024
[2]  
[Anonymous], 2005, EST MAX SAF START DO
[3]   Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy [J].
Burris, Howard A., III ;
Rugo, Hope S. ;
Vukelja, Svetislava J. ;
Vogel, Charles L. ;
Borson, Rachel A. ;
Limentani, Steven ;
Tan-Chiu, Elizabeth ;
Krop, Ian E. ;
Michaelson, Richard A. ;
Girish, Sandhya ;
Amler, Lukas ;
Zheng, Maoxia ;
Chu, Yu-Waye ;
Klencke, Barbara ;
O'Shaughnessy, Joyce A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) :398-405
[4]   Mathematical modeling of liver metastases tumour growth and control with radiotherapy [J].
Campbell, Adrienne ;
Sivakumaran, Thiru ;
Davidson, Melanie ;
Lock, Michael ;
Wong, Eugene .
PHYSICS IN MEDICINE AND BIOLOGY, 2008, 53 (24) :7225-7239
[5]   Brentuximab Vedotin [J].
Deng, Changchun ;
Pan, Beiqing ;
O'Connor, Owen A. .
CLINICAL CANCER RESEARCH, 2013, 19 (01) :22-27
[6]   Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data What have we learned? [J].
Deng, Rong ;
Iyer, Suhasini ;
Theil, Frank-Peter ;
Mortensen, Deborah L. ;
Fielder, Paul J. ;
Prabhu, Saileta .
MABS, 2011, 3 (01) :61-66
[7]   Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity [J].
Doronina, SO ;
Mendelsohn, BA ;
Bovee, TD ;
Cerveny, CG ;
Alley, SC ;
Meyer, DL ;
Oflazoglu, E ;
Toki, BE ;
Sanderson, RJ ;
Zabinski, RF ;
Wahl, AF ;
Senter, PD .
BIOCONJUGATE CHEMISTRY, 2006, 17 (01) :114-124
[8]   Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies [J].
Ducry, Laurent ;
Stump, Bernhard .
BIOCONJUGATE CHEMISTRY, 2010, 21 (01) :5-13
[9]  
Fayad L, 2008, BLOOD ASH ANN M
[10]   Prediction of Exposure-Response Relationships to Support First-in-Human Study Design [J].
Gibbs, John P. .
AAPS JOURNAL, 2010, 12 (04) :750-758